Abstract
Chronic hepatitis B infection remains a global health burden despite existence of an eff ective vaccine. Infection with chronic hepatitis B and its sequelae lead to almost 800 000 deaths annually. Over the past decades, treatment of chronic hepatitis B has evolved considerably. Treatment with tenofovir disoproxil fumarate achieves viral suppression in more than 90% of patients during continuous therapy and leads to reversal of liver cirrhosis. Unfortunately, since loss of hepatitis B surface antigen (HBsAg) is rarely achieved and might take up to 30 years, treatment with tenofovir disoproxil fumarate is indefinite. [...]
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
